<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2679278-A1" country="EP" doc-number="2679278" kind="A1" date="20140101" family-id="41587870" file-reference-id="318273" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146550408" ucid="EP-2679278-A1"><document-id><country>EP</country><doc-number>2679278</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13159487-A" is-representative="NO"><document-id mxw-id="PAPP154824331" load-source="docdb" format="epo"><country>EP</country><doc-number>13159487</doc-number><kind>A</kind><date>20090929</date><lang>EN</lang></document-id><document-id mxw-id="PAPP199413583" load-source="docdb" format="original"><country>EP</country><doc-number>13159487.1</doc-number><date>20090929</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140449320" ucid="EP-08169547-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>08169547</doc-number><kind>A</kind><date>20081120</date></document-id></priority-claim><priority-claim mxw-id="PPC140455203" ucid="EP-09783522-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>09783522</doc-number><kind>A</kind><date>20090929</date></document-id></priority-claim><priority-claim mxw-id="PPC140450583" ucid="EP-13159487-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>13159487</doc-number><kind>A</kind><date>20090929</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1836143569" load-source="docdb">A61Q  19/00        20060101AFI20170303BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1836143570" load-source="docdb">A61P  17/16        20060101ALI20170303BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1836143571" load-source="docdb">A61K  31/726       20060101ALI20170303BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1836143572" load-source="docdb">A61K   8/73        20060101ALI20170303BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1702765131" load-source="docdb" scheme="CPC">A61Q  19/004       20130101 LI20180202BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1702765132" load-source="docdb" scheme="CPC">A61K2800/75        20130101 LA20180202BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1702765133" load-source="docdb" scheme="CPC">A61Q  19/00        20130101 LI20180202BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1841949958" load-source="docdb" scheme="CPC">A61Q  19/08        20130101 LA20161126BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1841949959" load-source="docdb" scheme="CPC">A61Q  19/02        20130101 LA20160427BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1873986481" load-source="docdb" scheme="CPC">A61K  31/727       20130101 LI20161124BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1873986482" load-source="docdb" scheme="CPC">A61K   8/73        20130101 FI20161126BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1946289544" load-source="docdb" scheme="CPC">A61K2800/522       20130101 LA20160427BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1946289545" load-source="docdb" scheme="CPC">A61K  31/726       20130101 LI20160427BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132183708" lang="DE" load-source="patent-office">Dermatologische Zusammensetzungen mit Heparansulfat</invention-title><invention-title mxw-id="PT132183709" lang="EN" load-source="patent-office">Dermatological compositions comprising heparan sulfate</invention-title><invention-title mxw-id="PT132183710" lang="FR" load-source="patent-office">Compositions dermatologiques comprenant du sulfate d'héparane</invention-title><citations><patent-citations><patcit mxw-id="PCIT367660954" load-source="docdb" ucid="EP-0297455-A1"><document-id format="epo"><country>EP</country><doc-number>0297455</doc-number><kind>A1</kind><date>19890104</date></document-id><sources><source name="SEA" category="XY" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT367660956" load-source="docdb" ucid="US-20030103916-A1"><document-id format="epo"><country>US</country><doc-number>20030103916</doc-number><kind>A1</kind><date>20030605</date></document-id><sources><source name="SEA" category="XY" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT367660955" load-source="docdb" ucid="US-5902798-A"><document-id format="epo"><country>US</country><doc-number>5902798</doc-number><kind>A</kind><date>19990511</date></document-id><sources><source name="SEA" category="XY" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>"European Pharmacopeia"</text><sources><source mxw-id="PNPL59619644" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>"European Pharmacopoeia", pages: 1297</text><sources><source mxw-id="PNPL59619645" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BEYTH R J ET AL: "Glycosaminoglycan distribution in substratum adhesion sites of aging human skin fibroblasts, including papillary and reticular subpopulations", MECHANISMS OF AGEING AND DEVELOPMENT, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 29, no. 2, 1 February 1985 (1985-02-01), pages 151 - 169, XP025196844, ISSN: 0047-6374, [retrieved on 19850201], DOI: DOI:10.1016/0047-6374(85)90015-6</text><sources><source mxw-id="PNPL59619646" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>R. CAPPELLETTI ET AL.: "A new Electrophoretic method for the separation of all Gags", ANAL. BIOCHEM., vol. 99, 1979, pages 311 - 315, XP055155220, DOI: doi:10.1016/S0003-2697(79)80012-3</text><sources><source mxw-id="PNPL70468518" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>V. PRATHIBA; S. GUPTA: "Cutaneous wound healing: Significance of proteoglycans in scar formation", CURRENT SCIENCE, vol. 78, no. 6, 2000</text><sources><source mxw-id="PNPL59619648" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>VAN HORSSEN J ET AL: "Heparan sulphate proteoglycans in Alzheimer's disease and amyloid@?related disorders", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 2, no. 8, 1 August 2003 (2003-08-01), pages 482 - 492, XP004810293, ISSN: 1474-4422, DOI: DOI:10.1016/S1474-4422(03)00484-8</text><sources><source mxw-id="PNPL59619649" load-source="docdb" name="SEA" category="A"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-13159487-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13159487</doc-number><kind>A</kind><date>20090929</date></document-id></child-doc><parent-doc ucid="EP-09783522.7"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>09783522.7</doc-number><date>20090929</date></document-id><parent-grant-document ucid="EP-2346573-B1"><document-id><country>EP</country><doc-number>2346573</doc-number><kind>B1</kind><date>20140625</date></document-id></parent-grant-document></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR918143788" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DERIVATI ORGANICI LAB</last-name><address><country>IT</country></address></addressbook></applicant><applicant mxw-id="PPAR918146471" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LABORATORI DERIVATI ORGANICI S.P.A.</last-name></addressbook></applicant><applicant mxw-id="PPAR918979988" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>LABORATORI DERIVATI ORGANICI S.P.A.</last-name><iid>100162901</iid><address><street>Via M. Barozzi, 4</street><city>20122 Milano</city><country>IT</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918162586" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DE AMBROSI LUIGI</last-name><address><country>IT</country></address></addressbook></inventor><inventor mxw-id="PPAR918139499" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DE AMBROSI, LUIGI</last-name></addressbook></inventor><inventor mxw-id="PPAR918987366" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>DE AMBROSI, LUIGI</last-name><address><street>Via Carducci, 8</street><city>13048 Santhià (VC)</city><country>IT</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918989526" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Serravalle, Marco</last-name><iid>101166497</iid><address><street>Serravalle SAS Via Matteotti, 21/23</street><city>26854 Cornegliano Laudense (LO)</city><country>IT</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS548905686" load-source="docdb">AT</country><country mxw-id="DS548811280" load-source="docdb">BE</country><country mxw-id="DS548909519" load-source="docdb">BG</country><country mxw-id="DS548827214" load-source="docdb">CH</country><country mxw-id="DS548811281" load-source="docdb">CY</country><country mxw-id="DS548893704" load-source="docdb">CZ</country><country mxw-id="DS548857419" load-source="docdb">DE</country><country mxw-id="DS548811282" load-source="docdb">DK</country><country mxw-id="DS548811283" load-source="docdb">EE</country><country mxw-id="DS548908412" load-source="docdb">ES</country><country mxw-id="DS548909520" load-source="docdb">FI</country><country mxw-id="DS548909521" load-source="docdb">FR</country><country mxw-id="DS548857420" load-source="docdb">GB</country><country mxw-id="DS548811284" load-source="docdb">GR</country><country mxw-id="DS548857421" load-source="docdb">HR</country><country mxw-id="DS548893705" load-source="docdb">HU</country><country mxw-id="DS548827215" load-source="docdb">IE</country><country mxw-id="DS548811285" load-source="docdb">IS</country><country mxw-id="DS548909522" load-source="docdb">IT</country><country mxw-id="DS548811286" load-source="docdb">LI</country><country mxw-id="DS548909523" load-source="docdb">LT</country><country mxw-id="DS548905687" load-source="docdb">LU</country><country mxw-id="DS548909524" load-source="docdb">LV</country><country mxw-id="DS548909525" load-source="docdb">MC</country><country mxw-id="DS548905688" load-source="docdb">MK</country><country mxw-id="DS548905689" load-source="docdb">MT</country><country mxw-id="DS548908413" load-source="docdb">NL</country><country mxw-id="DS548914701" load-source="docdb">NO</country><country mxw-id="DS548908418" load-source="docdb">PL</country><country mxw-id="DS548905694" load-source="docdb">PT</country><country mxw-id="DS548827216" load-source="docdb">RO</country><country mxw-id="DS548908419" load-source="docdb">SE</country><country mxw-id="DS548893706" load-source="docdb">SI</country><country mxw-id="DS548914918" load-source="docdb">SK</country><country mxw-id="DS548914919" load-source="docdb">SM</country><country mxw-id="DS548909526" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128671075" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention relates to dermatological compositions comprising heparan sulfate. The heparan sulphate for use in the compositions of the invention has molecular weight by weight comprised between 6,000 Da and 12,000 Da. The dermatological compositions according to the invention comprise heparan sulphate in an amount comprised between 0.01 wt% and 5 wt%.</p><p id="pa02" num="0002">The dermatological compositions according to the invention show, inter alia, lenitive effect.</p></abstract><abstract mxw-id="PA128500448" lang="EN" source="EPO" load-source="docdb"><p>The present invention relates to dermatological compositions comprising heparan sulfate. The heparan sulphate for use in the compositions of the invention has molecular weight by weight comprised between 6,000 Da and 12,000 Da. The dermatological compositions according to the invention comprise heparan sulphate in an amount comprised between 0.01 wt% and 5 wt%.  The dermatological compositions according to the invention show, inter alia, lenitive effect.</p></abstract><description mxw-id="PDES63956505" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">The invention relates to a new process for the purification of heparan sulfate. The present invention also relates to cosmetological and dermatological preparations making use of heparan sulfate.</p><p id="p0002" num="0002">Heparans are extracted from heparinoids which constitutes a byproduct in the purification of heparin from pig intestinal mucosa. They are structural isomers formed during synthesis of glycosaminoglycanes (GAGs); highly sulfated and epimerised structures are typical of heparin, while highly epimerised and less N- and O- sulfated structures are typical of heparin-like structures presenting low anticoagulant activity.</p><p id="p0003" num="0003">It is known that endogenous proteoglycans (PG) play an important role in wound healing (<nplcit id="ncit0001" npl-type="s"><text>V. Prathiba and S. Gupta: Cutaneous wound healing: Significance of proteoglycans in scar formation". Current Science, vol. 78, n°6, 2000</text></nplcit>). However, the prior art does not describe the effect of administration of proteoglycans and, more specifically, of heparan sulfate in cosmetological and dermatological applications.</p><p id="p0004" num="0004">The present invention relates to cosmetological and dermatological preparations comprising heparan sulfate, and their use as whitening, anti-wrinkle, lenitive and anti-oxidant agent. It has been surprisingly found that heparan sulfate is effective in the treatment of the above mentioned conditions.</p><p id="p0005" num="0005">In a further embodiment, the invention is directed to medical devices making use of heparan sulfate in the cosmetological and dermatological field.</p><p id="p0006" num="0006">In another preferred embodiment, the present invention is directed to a process for the purification of heparan sulfate, which process allows the use of pure heparan sulfate in dermatological and cosmetological applications.</p><p id="p0007" num="0007">In a preferred embodiment, the cosmetological and dermatological preparations according to the invention make use of purified heparan sulfate. In fact, purification of heparan sulfate is an important step in order to remove residual compounds which are extracted with heparan sulfate but present different characteristics.<!-- EPO <DP n="2"> --></p><p id="p0008" num="0008">The purification process of the invention is characterized by the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin under conditions which result in selective desorption of heparan sulfate.</p><p id="p0009" num="0009">The anion exchange resin is preferably a strong base macroporous anion exchange resin such as, for example, Lewatit™ S 6328 A. The adsorption is performed by mixing a sufficient amount of resin beads. Preferably the amount of beads is higher than 15 g of resin per gram of heparan sulfate, more preferably is comprised between 18 and 25 g resin per gram of heparan sulfate.</p><p id="p0010" num="0010">After adsorption on the anion exchange resin, heparan sulfate is selectively desorbed by using an alkaline or alkaline earth metal salt, preferably an halogenide or an acetate. Examples of suitable salts are magnesium dichloride, magnesium diacetate, sodium chloride, sodium acetate, potassium chloride and potassium acetate. The pH of the salt solution is preferably comprised between 7.0 and 10.0. The concentration of the salt is important in order to achieve complete and selective desorption of heparan sulfate. A preferred range of concentration is comprised between 0.3 M and 1.0 M, more preferably between 0.5 M and 0.8 M. In fact, if the concentration of the salt is too low, the desorption of heparan sulfate is incomplete. If the concentration is too high, the desorption is not selective and, together with heparan sulfate, also highly sulfated compounds are desorbed.</p><p id="p0011" num="0011">After desorption from the anion exchange resin, heparan sulfate is optionally further passed on a cationic resin and on a anionic resin. An example of suitable anionic resin is Amberlite Forte IR 120™. An example of a suitable cationic resin is Amberlite Forte IRA 410™.</p><p id="p0012" num="0012">Purified heparan sulfate according to the invention was tested in various dermatological and cosmetological applications. More specifically, heparan sulfate was tested for whitening, lenitive and anti-age effects. In all these applications heparan sulfate showed a significant activity.</p><p id="p0013" num="0013">A preferred embodiment of the present invention is directed to a cosmetological composition comprising heparan sulfate.</p><p id="p0014" num="0014">Preferably, the cosmetological compositions according to the invention comprise from 0.01 % by weight to 5 % by weight of heparan sulfate,<!-- EPO <DP n="3"> --> more preferably from 0.05 % by weight to 2 % by weight, even more preferably from 0.1 % by weight to 1.0 % by weight.</p><p id="p0015" num="0015">The molecular weight by weight (Mw) of the heparan sulfate suitable in the cosmetological and dermatological applications of the invention is preferably comprised between 6,000 and 12,000 Da.</p><p id="p0016" num="0016">The cosmetological compositions according to the invention optionally comprise other substances such as preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, which are usually included in cosmetological and dermatological compositions.</p><p id="p0017" num="0017">In a preferred embodiment, the compositions according to the present invention are used as anti-age product. Many anti-age products often claim their ability to induce an increase in cell proliferation or in the protein synthesis on fibroblasts, with a linked improvement in cell firmness and thickness.</p><p id="p0018" num="0018">Fibroblasts are the main cell component in the connective tissue of the dermis and they are able to synthesize high amount of collagen and elastin, the main components of the dermis that play an essential role in the skin thickness and appearance. The increase in protein amount for cell stimulates the ability of fibroblasts to synthetize collagen and elastin.</p><p id="p0019" num="0019">Another claim for anti-aging and protective cosmetics is their activity in counteracting oxidative stress and free-radicals release in the skin. Oxidative stress is one of the main cause of aging process and is involved in the development of many serious human diseases. Exposure to UVA rays, pollutants, tobacco's smoke, as well as diet, drugs intake or pathologies can increase the level of oxidant activity in the skin cells or decrease the effectiveness of endogenous antioxidant systems. Following exposure to oxidative stress Reactive Oxygen Species (ROS) formation, damages to the cells membrane and to DNA may occur in the cell, leading to cell transformation or even death.<br/>
The induction of fibroblasts proliferation and protein synthesis in dermis cells are of great concern for actives targeted to anti-age topical products.</p><p id="p0020" num="0020">It has been found that compositions comprising heparan sulfate are effective both as anti-wrinkle compositions and as anti-oxidant compositions.<!-- EPO <DP n="4"> --></p><heading id="h0001"><b>Experimental</b></heading><p id="p0021" num="0021">Organic sulfur, Uronic acid, Glucosamine, Optical rotation, total nitrogen and APTT were measured in accordance with the <nplcit id="ncit0002" npl-type="b"><text>European Pharmacopeia, 4th editi</text></nplcit>on. Electrophoresis was performed in accordance with <nplcit id="ncit0003" npl-type="s"><text>R. Cappelletti et al. "A new Electrophoretic method for the separation of all Gags" Anal. Biochem. 99:311-315 (1979</text></nplcit>).</p><p id="p0022" num="0022">Molecular mass (M<sub>w</sub>) was determined by size exclusion chromatography (<nplcit id="ncit0004" npl-type="b"><text>European Pharmacopoeia 4th ed.: 2.2.30 and 2.2.46 for chromatography techniques and 01/2002:0828 p.1297 </text></nplcit>for method).</p><heading id="h0002"><b>Purification of Heparan Sulfate</b></heading><p id="p0023" num="0023">5 g of heparan sulfate from pig intestinal mucosa were dissolved in 200 ml of demineralised water. 90 g of Lewatit S 6238 A™ were added to the solution. The mixture was slowly stirred at room temperature for 72 h and then filtered. The filtrate was analysed and no heparan sulfate was detected.</p><p id="p0024" num="0024">The resin was washed, transferred in a column (diameter 3 cm, length 40 cm) and eluted with a 5 % by weight solution of MgCl<sub>2</sub> at pH 8.5.</p><p id="p0025" num="0025">The first 300 ml are collected, after which the solution did not show presence of heparan sulfate (negative reaction to quaternary ammonium).</p><p id="p0026" num="0026">The solution is brought to pH = 6 with a 10 % solution of hydrochloric acid and heparan sulfate is precipitated by adding 600 ml of acetone. The suspension is left at 15 °C for 12 h. Then the solid is collected, dissolved in 50 ml of water and precipitated by adding 100 ml of acetone.</p><p id="p0027" num="0027">Heparan sulfate is then dissolved in 100 ml of water and the solution is passed over a resin Amberlite Forte IR 120™ and then over a resin Amberlite Forte IRA 410™. The eluate is neutralized by adding a 5 % by weight solution of NaOH until pH 6. Water is evaporated under vacuum, the solid is filtered on a 0.45 µm filter and lyophilised. Yield: 4.12 g.</p><p id="p0028" num="0028">Analysis: Rotation = +50.62°. Organic S = 9.07%. Uronic acid = 31.97 %. Glucosamine = 37%. Total N = 2.26%. APTT = 6.31 U/mg. Mw = 7538 Da (Before purification 8729 Da).<!-- EPO <DP n="5"> --></p><heading id="h0003"><b>TEST for WHITENING EFFICACY EVALUATION</b></heading><heading id="h0004"><b>In vitro evaluation of the bleaching activity of a raw material on cell cultures - Test Procedure</b></heading><p id="p0029" num="0029">The in vitro whitening effect of HS was detected by measurement of melanin content on melanoma cells B16 (fibroblast-like cells able to produce melanin) after 6 days of contact with HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).</p><p id="p0030" num="0030">The negative control (NC) was represented by untreated cells (cell without any substance). The positive control (PC) was represented by cells treated with Hydroquinone 5 µg/ml (0.0005%). On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro whitening effect.
<tables id="tabl0001" num="0001"><table frame="all"><title><b>Table I</b></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="47mm"/><colspec colnum="2" colname="col2" colwidth="60mm"/><colspec colnum="3" colname="col3" colwidth="60mm"/><thead><row><entry valign="middle"/><entry valign="middle"><b>Melanin Content</b> (µg melanin/mg protein)</entry><entry valign="middle"><b>% Melanin Synthesis Inhibition vs NC</b></entry></row></thead><tbody><row><entry>HS (0.01%)</entry><entry align="char" char=".">41.9</entry><entry>10.3</entry></row><row><entry>HS (0.005%)</entry><entry align="char" char=".">44.4</entry><entry>5.2</entry></row><row><entry>PC: Hydroquinone (0.0005%)</entry><entry align="char" char=".">10.8</entry><entry>76.8</entry></row><row><entry>NC: untreated cells</entry><entry align="char" char=".">46.8</entry><entry>---</entry></row></tbody></tgroup></table></tables></p><heading id="h0005"><b>In vivo - Whitening efficacy evaluation of a cosmetic formulation on 20 volunteers</b></heading><heading id="h0006"><b>Test Procedure :</b></heading><p id="p0031" num="0031">The test was performed in the single blind mode. 20 volunteers (age between 40-50 years) with aged spots where present (hand, forehead, arm, face, neck). The region with aged spots was divided in two zone: one for the treatment with tested substance, one with placebo. The spots were treated for<!-- EPO <DP n="6"> --> 30 consecutive days: 1 application (1mg of substance) / die on tested area (150-200 cm<sup>2</sup>) [as per Colipa guideline].</p><p id="p0032" num="0032">The tested substance was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.</p><p id="p0033" num="0033">Placebo was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.</p><p id="p0034" num="0034">The evaluation (MI - Melanin Index by Mexameter MX 18) was made in the following way:<br/>
T<sub>0</sub> - basal value, value of Melanin Index before the application of substance.<br/>
T<sub>15</sub> - value of Melanin Index after 15 days of substance application.<br/>
T<sub>30</sub> - final value, value of Melanin Index at the end of test (after 30 days of substance application).
<tables id="tabl0002" num="0002"><table frame="all"><title><b>Table II</b></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="18mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><thead><row><entry valign="top"/><entry valign="top"><b>T<sub>0</sub></b> MI ± std dev</entry><entry valign="top"><b>T<sub>15</sub></b> MI ± std dev</entry><entry valign="top"><b>T<sub>30</sub></b> MI ± std dev</entry></row></thead><tbody><row><entry>HS 0.9 %</entry><entry>229.09 ± 44.06</entry><entry>222.00 ± 58.37</entry><entry>220.81 ± 54.25</entry></row><row><entry>Placebo</entry><entry>199.89 ± 55.89</entry><entry>205.84 ± 55.95</entry><entry>215.07 ± 75.45</entry></row></tbody></tgroup></table></tables></p><p id="p0035" num="0035">The decrease of MI (Melanin Index) in the area treated with tested substance, versus MI treated with placebo, after 30 days of application, resulted statistically relevant (p&lt; 0.01). Hence the Whitening Effect of tested substance (emulsion with 0.9% Heparan Sulphate sodium salt) was confirmed.</p><heading id="h0007"><b>TEST for LENITIVE EFFICACY EVALUATION</b></heading><heading id="h0008"><b>In vitro - Degranulation test on basophil cells with cosmetic raw materials - Test Procedure</b></heading><!-- EPO <DP n="7"> --><p id="p0036" num="0036">Basophil cells, when come in contact with irritant substances, give their biochemical response that is the secretion (by degranulation) of substances (such as histamine, leukotriens, proteolytic enzymes as hexosaminidase) that contribute to inflammatory events.</p><p id="p0037" num="0037">Inhibition in basophil cells degranulation is a measure of lenitive (anti-itching) effect of a substance. The in vitro lenitive effect of HS was detected by measurement of the release of β-hexosaminidase after 2 h of contact with HS at 4 different concentrations: 10 mg/ml (1%), 5 mg/ml (0.5%), 1 mg/ml (0.1%), 0.2 mg/ml (0.02%).</p><p id="p0038" num="0038">The negative control (NC) was represented by untreated cells (cells without any substance). The positive control (PC) was represented by basophil degranulation stimul (by crosslinking the receptor FcεRI with a specific polyclonal antibody against to the α-chain stimulate the degranulation). The maximal stimulation (degranulation) is : cell treated with 1% Triton X-100. The results are reported as Optical Density (OD) at 405 nm.
<tables id="tabl0003" num="0003"><table frame="all"><title><b>Table III</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="43mm"/><colspec colnum="2" colname="col2" colwidth="67mm"/><thead><row><entry valign="top"/><entry valign="top"><b>release of β-hexosaminidase</b> OD at 450 nm</entry></row></thead><tbody><row><entry>NC : untreated cells</entry><entry align="char" char="." charoff="3">0.054</entry></row><row><entry>PC : basophil degranulation</entry><entry align="char" char="." charoff="3">0.117</entry></row><row><entry>Max Stimulation</entry><entry align="char" char="." charoff="3">0.377</entry></row><row><entry>HS 10 mg/ml</entry><entry align="char" char="." charoff="3">0.066</entry></row><row><entry>HS 5 mg/ml</entry><entry align="char" char="." charoff="3">0.059</entry></row><row><entry>HS 1 mg/ml</entry><entry align="char" char="." charoff="3">0.062</entry></row><row><entry>HS 0.2 mg/ml</entry><entry align="char" char="." charoff="3">0.061</entry></row><row><entry>HS 10 mg/ml + PC</entry><entry align="char" char="." charoff="3">0.061</entry></row><row><entry>HS 5 mg/ml + PC</entry><entry align="char" char="." charoff="3">0.055</entry></row><row><entry>HS 1 mg/ml + PC</entry><entry align="char" char="." charoff="3">0.110</entry></row><row><entry>HS 0.2 mg/ml + PC</entry><entry align="char" char="." charoff="3">0.112</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="8"> --></p><p id="p0039" num="0039">On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro lenitive effect.</p><p id="p0040" num="0040">The β-hexosaminidase "natural" level, level without any contact with irritant substance is 0.054 (OD at 450 nm). HS alone (at different concentration) has the same effect of negative control, that means leaves the cell with their "natural" level of β-hexosaminidase. This confirms that HS has no effect on basophil cells degranulation.</p><p id="p0041" num="0041">When the cells come in contact with an irritant substance (positive control) the value increase at 0.117, or higher to 0.377 when in contact with Triton X-100 (1%).</p><p id="p0042" num="0042">When the cells come in contact both with an irritant substance (positive control) and HS the level of β-hexosaminidase decrease in a dose dependent way, with best efficacy with HS at 0.5% and 1%, hence HS has a lenitive (anti-itching) effect.</p><heading id="h0009"><b>In vivo - Lenitive efficacy evaluation on a cosmetic formulation on 20 volunteers - short term test - Test Procedure</b></heading><p id="p0043" num="0043">The test was performed in single blind mode. 20 volunteers (age between 36-52 years) were treated on a circumscribed treated zone of 1 cm<sup>2</sup> on the back of each volunteer : one for test substance application, one for placebo application, and one for control (untreated zone). The test was performed by a single application (2mg of substance) on tested area (1 cm<sup>2</sup>) [as per Colipa guideline]. Total time : 60 minutes after application</p><p id="p0044" num="0044">Tested substance was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.</p><p id="p0045" num="0045">Placebo was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.<!-- EPO <DP n="9"> --></p><p id="p0046" num="0046">The transient erythemagenic reaction is induced by exposure to a known amount of UVB radiation coming from a Solar Stimulator. The evaluation (EI - Erythema Index by Mexameter MX 18) were made in the following way:
<ul><li>o T<sub>0</sub> - basal value, value of Erythema Index after UVB radiation and before the application of substance</li><li>o T<sub>15</sub> -value of Erythema Index after 15 minutes from substance application</li><li>o T<sub>30</sub> -value of Erythema Index after 30 minutes from substance application</li><li>o T<sub>60</sub> -value of Erythema Index after 60 minutes from substance application</li></ul>
<tables id="tabl0004" num="0004"><table frame="all"><title><b>Table IV</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="30mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><colspec colnum="5" colname="col5" colwidth="27mm"/><thead><row><entry valign="top"/><entry valign="top"><b>T<sub>0</sub></b> EI ± std dev</entry><entry valign="top"><b>T<sub>15</sub></b> EI ± std dev</entry><entry valign="top"><b>T<sub>30</sub></b> EI ± std dev</entry><entry valign="top"><b>T<sub>60</sub></b> EI ± std dev</entry></row></thead><tbody><row><entry>Tested Substance</entry><entry>455.75 ± 64.63</entry><entry>439.55 ± 82.67</entry><entry>421.59 ± 72.31</entry><entry>406.39 ± 77.06</entry></row><row><entry>Placebo</entry><entry>453.21 ± 71.50</entry><entry>430.26 ± 76.22</entry><entry>415.69 ± 67.42</entry><entry>415.79 ± 75.18</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0005" num="0005"><table frame="all"><title><b>Table V</b></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="30mm"/><colspec colnum="2" colname="col2" colwidth="18mm"/><colspec colnum="3" colname="col3" colwidth="18mm"/><colspec colnum="4" colname="col4" colwidth="18mm"/><thead><row><entry valign="top"/><entry valign="top"><b>T<sub>0</sub> vs T<sub>15</sub></b></entry><entry valign="top"><b>T<sub>0</sub> vs T<sub>30</sub></b></entry><entry valign="top"><b>T<sub>0</sub> vs T<sub>60</sub></b></entry></row></thead><tbody><row><entry>Tested Substance</entry><entry>- 4.19</entry><entry>- 8.29</entry><entry>- 11.24</entry></row><row><entry>Placebo</entry><entry>- 5.36</entry><entry>- 8.29</entry><entry>- 8.58</entry></row></tbody></tgroup></table></tables></p><p id="p0047" num="0047">The decrease of EI (Erythema Index) in the area treated with tested substance, versus EI treated with placebo, after 60 minutes from application, resulted statistically relevant (p&lt; 0.1), and is statistically relevant (p&lt; 0.01) the decrease after 60 minutes versus basal value. Hence the Lenitive (redness reduction) Effect of tested substance (emulsion with 0.9% Heparan Sulphate sodium salt) has been confirmed.</p><heading id="h0010"><b>TEST for ANTI-WRINKLE EFFICACY EVALUATION</b></heading><!-- EPO <DP n="10"> --><p id="p0048" num="0048">In vitro Evaluation of the anti-ageing activity of cosmetic products through the investigation of their anti-oxidant and protective activity against UVA on human keratinocytes cell cultures.</p><heading id="h0011"><b>Test Procedure</b></heading><p id="p0049" num="0049">The antioxidant effect of HS is detected by measurement of reduction of free radicals as Reactive Oxygen Species (ROS) after exposure to 3 different UVA irradiation for 1 minute and 30 seconds (1' 30"), for 3 minutes (3') and for 4 minutes and 30 seconds (4' 30"), with HS at 7 different concentrations: 0.031 mg/ml (0.0031%), 0.063 mg/ml (0.0063%), 0.125 mg/ml (0.0125%), 0.250 mg/ml (0.0250%), 0.500 mg/ml (0.0500%), 1.000 mg/ml (0.1000%) and 9.000 mg/ml (0.9000%). The negative control (NC) was: untreated cells (cells without any substance). The positive control (PC) was: Vitamin C (0.15 mg/ml) (0.015%).</p><p id="p0050" num="0050">Table VI shows the results obtained. It is evident that heparan sulphate sodium salt (HS) shows in vitro antioxidant effect. The efficacy of HS at 0.1% concentration is comparable or even higher than the efficacy of Vitamin C. The efficacy of HS is higher that Vitamin C even at prolonged exposure to UVA radiation (4' 30").
<tables id="tabl0006" num="0006"><table frame="all"><title><b>Table VI</b></title><tgroup cols="10"><colspec colnum="1" colname="col1" colwidth="29mm"/><colspec colnum="2" colname="col2" colwidth="19mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="14mm"/><colspec colnum="5" colname="col5" colwidth="14mm"/><colspec colnum="6" colname="col6" colwidth="14mm"/><colspec colnum="7" colname="col7" colwidth="14mm"/><colspec colnum="8" colname="col8" colwidth="14mm"/><colspec colnum="9" colname="col9" colwidth="14mm"/><colspec colnum="10" colname="col10" colwidth="21mm"/><thead><row><entry rowsep="0" valign="top"/><entry rowsep="0" valign="top">Exposure</entry><entry namest="col3" nameend="col9" align="center" valign="top">Heparan Sulphate Sodium Salt mg/ml</entry><entry valign="top">Vit C mg/ml</entry></row><row><entry valign="top"/><entry valign="top"/><entry valign="top">9.000</entry><entry valign="top">1.000</entry><entry valign="top">0.500</entry><entry valign="top">0.250</entry><entry valign="top">0.125</entry><entry valign="top">0.063</entry><entry valign="top">0.031</entry><entry valign="top">0.15</entry></row></thead><tbody><row><entry morerows="2">ROS Inhibition %</entry><entry>1'30" UVA</entry><entry>30.7</entry><entry>38.7</entry><entry>30.6</entry><entry>28.0</entry><entry>23.5</entry><entry>25.4</entry><entry>25.3</entry><entry>33.5</entry></row><row><entry>3'00" UVA</entry><entry>31.6</entry><entry>35.7</entry><entry>29.1</entry><entry>22.9</entry><entry>14.2</entry><entry>21.8</entry><entry>20.1</entry><entry>31.4</entry></row><row><entry>4'30" UVA</entry><entry>26.3</entry><entry>30.4</entry><entry>24.7</entry><entry>18.1</entry><entry>10.3</entry><entry>13.7</entry><entry>6.2</entry><entry>12.7</entry></row></tbody></tgroup></table></tables></p><heading id="h0012"><b>In vitro - Mitogenic activity evaluation of a raw material</b></heading><heading id="h0013"><b>Test Procedure :</b></heading><!-- EPO <DP n="11"> --><p id="p0051" num="0051">The mitogenic effect of HS is detected by measurement of fibroblast cells proliferation, measurement of protein synthesis after exposure for 48 hours and 72 hours, using HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%). The negative control (NC) is represented by untreated cells, the positive control (PC) is : EGF (Epidermal Growth Factor) (10 µg/ml) (0.001%).
<tables id="tabl0007" num="0007"><table frame="all"><title><b>Table VII</b></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="46mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><thead><row><entry valign="top"/><entry namest="col2" nameend="col3" align="left" valign="top"><b>% cell proliferation vs NC</b></entry></row><row><entry valign="top"/><entry valign="top"><b>48 h</b></entry><entry valign="top"><b>72 h</b></entry></row></thead><tbody><row><entry>PC : <b>EGF</b> (10 µg/ml) (<b>0.001%)</b></entry><entry align="char" char=".">112.5</entry><entry>121.6</entry></row><row><entry>HS 0.1 mg/ml <b>(0.01%)</b></entry><entry align="char" char=".">110.5</entry><entry>118.1</entry></row><row><entry>HS 0.05 mg/ml <b>(0.005%)</b></entry><entry align="char" char=".">106.7</entry><entry>1<b>18.2</b></entry></row><row><entry colsep="0"/><entry colsep="0"/><entry/></row></tbody></tgroup><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="46mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><thead><row><entry valign="top"/><entry namest="col2" nameend="col3" align="left" valign="top"><b>% protein synthesis vs NC</b></entry></row><row><entry valign="top"/><entry valign="top"><b>48 h</b></entry><entry valign="top"><b>72 h</b></entry></row></thead><tbody><row><entry>PC : <b>EGF</b> (10 µg/ml) <b>(0.001%)</b></entry><entry align="char" char=".">116.6</entry><entry>119.0</entry></row><row><entry>HS 0.1 mg/ml <b>(0.01%)</b></entry><entry align="char" char=".">103.1</entry><entry>113.2</entry></row><row><entry>HS 0.05 mg/ml <b>(0.005%)</b></entry><entry align="char" char=".">110.2</entry><entry>1<b>20.4</b></entry></row></tbody></tgroup></table></tables></p><p id="p0052" num="0052">On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro cell proliferation and protein synthesis efficacy. The highest effect (18.2% for cell proliferation and 20.4% for protein synthesis) is observed after 72 hour from exposure at 0.05 mg/ml.</p></description><claims mxw-id="PCLM56977441" lang="EN" load-source="patent-office"><!-- EPO <DP n="12"> --><claim id="c-en-0001" num="0001"><claim-text>Dermatological composition comprising heparan sulphate, wherein heparan sulphate has a molecular weight by weight comprised between 6,000 Da and 12,000 Da and wherein heparan sulfate is present at a concentration comprised between 0.01 % by weight and 5 % by weight</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>Dermatological composition according to claim 1 wherein heparan sulphate is present at a concentration comprised between 0.05 % by weight and 2 % by weight.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>Dermatological composition according to claim 1 wherein heparan sulphate is present at a concentration comprised between 0.1 % by weight and 1 % by weight.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>Dermatological composition according to claims 1-3 further comprising one or more of the following ingredients: preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, and other components which are included in cosmetological and dermatological compositions.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>Composition according to claims 1-4 for use as a lenitive agent.</claim-text></claim></claims><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="157" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="157" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
